Covered recipient · General Payments record
STEPHEN MICHAEL SCHLEICHER
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$2,644.53
133 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,464.55 | 131 |
| Education | $179.98 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | $609.09 | 18 |
| AbbVie Inc. | $472.99 | 25 |
| Janssen Biotech, Inc. | $350.29 | 22 |
| UCB, Inc. | $340.31 | 34 |
| Janssen Scientific Affairs, LLC | $188.00 | 2 |
| Lilly USA, LLC | $162.62 | 4 |
| PFIZER INC. | $85.75 | 5 |
| Regeneron Healthcare Solutions, Inc. | $80.99 | 4 |
| GENZYME CORPORATION | $75.38 | 5 |
| Incyte Corporation | $63.47 | 1 |
| ORGANOGENESIS INC. | $58.18 | 3 |
| Genentech USA, Inc. | $50.52 | 3 |
| Paratek Pharmaceuticals, Inc. | $47.57 | 3 |
| Galderma Laboratories, L.P. | $29.43 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.94 | 1 |
| Helsinn Therapeutics (U.S.), Inc. | $14.00 | 1 |
Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
STEPHEN MICHAEL SCHLEICHER
NPI 1861487449 · CMS profile ID 39262
Allopathic & Osteopathic Physicians / Dermatology
SUGARLOAF, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1861487449?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- STEPHEN MICHAEL SCHLEICHER, NPI 1861487449, CMS profile ID 39262. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861487449?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). STEPHEN MICHAEL SCHLEICHER, NPI 1861487449, CMS profile ID 39262. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861487449?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- STEPHEN MICHAEL SCHLEICHER, NPI 1861487449, CMS profile ID 39262, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1861487449?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
133 matching records · $2,644.53 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–133 of 133.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genentech USA, Inc. | $13.31 | 04/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835980069 | CMS |
| UCB, Inc. | $8.66 | 04/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807337263 | CMS |
| AbbVie Inc. | $12.05 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795985907 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $14.28 | 04/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851931897 | CMS |
| Janssen Biotech, Inc. | $14.93 | 04/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788761015 | CMS |
| Janssen Biotech, Inc. | $2.61 | 04/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788761053 | CMS |
| Janssen Biotech, Inc. | $79.99 | 03/29/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788761013 | CMS |
| UCB, Inc. | $22.86 | 03/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807299629 | CMS |
| Janssen Biotech, Inc. | $5.40 | 03/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788761051 | CMS |
| GENZYME CORPORATION | $14.93 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843403459 | CMS |
| Regeneron Healthcare Solutions, Inc. | $13.79 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809621837 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $67.63 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851931891 | CMS |
| GENZYME CORPORATION | $11.11 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843403455 | CMS |
| UCB, Inc. | $19.83 | 03/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807331289 | CMS |
| UCB, Inc. | $5.06 | 03/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807316809 | CMS |
| Lilly USA, LLC | $14.30 | 03/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818701877 | CMS |
| UCB, Inc. | $21.71 | 02/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807318555 | CMS |
| UCB, Inc. | $1.36 | 02/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807301839 | CMS |
| Janssen Biotech, Inc. | $10.92 | 02/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788761045 | CMS |
| Janssen Biotech, Inc. | $3.57 | 02/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788761047 | CMS |
| UCB, Inc. | $13.50 | 02/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807305587 | CMS |
| Janssen Biotech, Inc. | $9.22 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788761049 | CMS |
| Janssen Biotech, Inc. | $2.49 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788761043 | CMS |
| PFIZER INC. | $15.89 | 02/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832746885 | CMS |
| UCB, Inc. | $1.82 | 02/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807311381 | CMS |
| AbbVie Inc. | $21.84 | 01/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795985905 | CMS |
| Galderma Laboratories, L.P. | $13.56 | 01/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855301237 | CMS |
| ORGANOGENESIS INC. | $14.45 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835462495 | CMS |
| UCB, Inc. | $21.65 | 01/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807309735 | CMS |
| AbbVie Inc. | $16.67 | 01/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795985903 | CMS |
| Regeneron Healthcare Solutions, Inc. | $15.34 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809621835 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $87.70 | 01/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851931893 | CMS |
| GENZYME CORPORATION | $15.09 | 01/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843403433 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $988,653.24 | 445 |
| PY2024 | Recipient | $350.79 | 2 |
| PY2024 | Principal investigator | $578,899.60 | 232 |
| PY2023 | Recipient | $44,993.44 | 3 |
| PY2023 | Principal investigator | $246,322.57 | 84 |
| PY2022 | Recipient | $44,091.91 | 5 |
| PY2022 | Principal investigator | $109,384.41 | 13 |
| PY2021 | Recipient | $403,393.25 | 6 |
| PY2021 | Principal investigator | $225,295.49 | 139 |
| PY2020 | Recipient | $177,244.24 | 7 |
| PY2020 | Principal investigator | $116,795.58 | 23 |
| PY2019 | Recipient | $79,567.33 | 44 |
| PY2019 | Principal investigator | $51,766.90 | 13 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
445 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,194.00 | 12/22/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578988 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,800.00 | 12/22/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579009 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,388.00 | 12/22/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579058 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 12/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508328 |
| Principal investigator 1 | Incyte Corporation | $93.00 | 12/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508341 |
| Principal investigator 1 | Incyte Corporation | $231.00 | 12/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508345 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 12/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508349 |
| Principal investigator 1 | Incyte Corporation | $55.00 | 12/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508407 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 12/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508423 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $141.36 | 12/17/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158490 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,218.30 | 12/17/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158494 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,120.65 | 12/17/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158497 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 12/17/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158517 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,800.00 | 12/11/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578991 |
| Principal investigator 1 | Incyte Corporation | $693.00 | 12/08/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508383 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 12/08/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508392 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 12/08/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508396 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 12/08/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508400 |
| Principal investigator 1 | Incyte Corporation | $372.00 | 12/08/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508404 |
| Principal investigator 1 | Incyte Corporation | $220.00 | 12/08/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508411 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 12/08/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508430 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $436.77 | 12/03/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158506 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $528.98 | 12/03/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158510 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $85.00 | 12/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226099791 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $85.00 | 12/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226099804 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $50.00 | 12/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226099810 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 12/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578980 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,194.00 | 12/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578999 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,580.00 | 12/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579013 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,728.00 | 12/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579017 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,728.00 | 12/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579026 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 12/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579037 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,825.00 | 12/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579042 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 12/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579046 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 12/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579055 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 12/01/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508354 |
| Principal investigator 1 | Incyte Corporation | $186.00 | 12/01/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508370 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 12/01/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508374 |
| Principal investigator 1 | Incyte Corporation | $20.00 | 12/01/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508379 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 12/01/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508419 |
| Principal investigator 1 | Incyte Corporation | $462.00 | 12/01/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508427 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,031.00 | 12/01/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158502 |
| Principal investigator 1 | Incyte Corporation | $462.00 | 11/24/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508332 |
| Principal investigator 1 | Incyte Corporation | $186.00 | 11/24/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508336 |
| Principal investigator 1 | Incyte Corporation | $184.00 | 11/24/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508362 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 11/24/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508366 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 11/24/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508388 |
| Principal investigator 1 | Incyte Corporation | $20.00 | 11/24/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508415 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,602.00 | 11/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099798 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,992.50 | 11/14/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158514 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,838.75 | 11/14/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158522 |
| Principal investigator 1 | Amgen Inc. | $15,337.48 | 11/06/2025 | Non-covered Recipient Entity DANA M MAUCH, CRA, DBA DMMRESEARCH | A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) | No dispute reported | 06/30/2026 | 1246640623 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $11,725.00 | 11/04/2025 | Non-covered Recipient Entity Best Skin Research, Llc | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235998674 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 11/03/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578983 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,728.00 | 11/03/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578995 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 11/03/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579002 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,681.00 | 11/03/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579006 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 11/03/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579021 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $785.00 | 11/03/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579029 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 11/03/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579033 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,728.00 | 11/03/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579051 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,728.00 | 11/03/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579063 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,345.00 | 11/03/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211579067 |
| Principal investigator 1 | Incyte Corporation | $1,129.50 | 10/24/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508358 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,350.00 | 10/14/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226099647 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $246.00 | 10/13/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578961 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,010.00 | 10/06/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099642 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,825.00 | 10/02/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578941 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,728.00 | 10/02/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578945 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 10/02/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578949 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 10/02/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578953 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,728.00 | 10/02/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578956 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,728.00 | 10/02/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578965 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 10/02/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578968 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 10/02/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578971 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 10/02/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578975 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,071.25 | 09/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158460 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,637.50 | 09/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158464 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $150.00 | 09/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158484 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $150.00 | 09/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158487 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $360.00 | 09/22/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099634 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $325.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578729 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $585.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578737 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,352.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578739 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $585.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578743 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $164.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578769 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $585.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578780 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $585.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578784 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $455.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578804 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $585.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578834 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $33.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578838 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $325.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578846 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $260.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578862 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $455.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578870 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $585.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578877 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $55.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578882 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $325.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578886 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $64.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578898 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $676.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578907 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $650.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578911 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $585.00 | 09/12/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578928 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,048.20 | 09/08/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226099621 |
| Principal investigator 1 | Incyte Corporation | $186.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508240 |
| Principal investigator 1 | Incyte Corporation | $184.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508244 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508247 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508251 |
| Principal investigator 1 | Incyte Corporation | $20.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508259 |
| Principal investigator 1 | Incyte Corporation | $693.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508263 |
| Principal investigator 1 | Incyte Corporation | $55.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508267 |
| Principal investigator 1 | Incyte Corporation | $231.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508271 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508279 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508283 |
| Principal investigator 1 | Incyte Corporation | $93.00 | 09/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508296 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,728.00 | 09/04/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578765 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,580.00 | 09/04/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578773 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $785.00 | 09/04/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578788 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,580.00 | 09/04/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578792 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 09/04/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578812 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,728.00 | 09/04/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578830 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,194.00 | 09/04/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578854 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,580.00 | 09/04/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578889 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 09/04/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578915 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 09/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508304 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,932.00 | 09/03/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099615 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 09/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527893 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $480.00 | 08/25/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099626 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $338.00 | 08/13/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578822 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $86.00 | 08/13/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578920 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,676.00 | 08/13/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578933 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,488.75 | 08/13/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158456 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,654.90 | 08/11/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099191 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,035.10 | 08/11/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226099197 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $436.25 | 08/08/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158472 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $303.75 | 08/08/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158476 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $557.50 | 08/08/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158480 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $676.00 | 08/06/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578752 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $123.00 | 08/06/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578858 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,352.00 | 08/06/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578894 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,272.00 | 08/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099177 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,200.00 | 08/01/2025 | Non-covered Recipient Entity Vial Health Technologies Inc | A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1235991963 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,580.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578733 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,395.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578748 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,681.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578756 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,345.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578761 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,395.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578776 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,825.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578795 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,681.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578799 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,825.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578808 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,681.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578816 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,681.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578827 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,580.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578842 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578850 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,194.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578866 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,194.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578903 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,395.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578925 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,534.00 | 08/01/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578937 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $300.00 | 07/28/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099183 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,370.00 | 07/21/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099165 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 07/18/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508275 |
| Principal investigator 1 | Incyte Corporation | $177.00 | 07/18/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508287 |
| Principal investigator 1 | Incyte Corporation | $41.00 | 07/18/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508291 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 07/18/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508300 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 07/18/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508316 |
| Principal investigator 1 | Incyte Corporation | $539.00 | 07/18/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508321 |
| Principal investigator 1 | Incyte Corporation | $1,463.90 | 07/16/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508308 |
| Principal investigator 1 | Incyte Corporation | $1,314.00 | 07/16/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508312 |
| Principal investigator 1 | Incyte Corporation | $1,255.00 | 07/16/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508325 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,800.00 | 07/09/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158468 |
| Principal investigator 1 | Incyte Corporation | $525.00 | 07/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508212 |
| Principal investigator 1 | Incyte Corporation | $449.40 | 07/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508225 |
| Principal investigator 1 | Incyte Corporation | $562.00 | 07/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508234 |
| Principal investigator 1 | Incyte Corporation | $443.52 | 07/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508255 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,080.00 | 07/07/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099158 |
| Principal investigator 1 | Incyte Corporation | $539.00 | 07/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508205 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 07/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508208 |
| Principal investigator 1 | Incyte Corporation | $177.00 | 07/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508216 |
| Principal investigator 1 | Incyte Corporation | $123.00 | 07/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508221 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 07/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508230 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $180.00 | 07/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099137 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,212.40 | 07/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099145 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,673.75 | 07/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158452 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 07/01/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527890 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 06/25/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508083 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 06/25/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508101 |
| Principal investigator 1 | Incyte Corporation | $1,258.00 | 06/20/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508104 |
| Principal investigator 1 | Incyte Corporation | $1,460.00 | 06/20/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508115 |
| Principal investigator 1 | Genentech, Inc. | $2,194.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578618 |
| Principal investigator 1 | Genentech, Inc. | $1,825.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578622 |
| Principal investigator 1 | Genentech, Inc. | $1,534.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578630 |
| Principal investigator 1 | Genentech, Inc. | $2,194.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578634 |
| Principal investigator 1 | Genentech, Inc. | $1,395.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578638 |
| Principal investigator 1 | Genentech, Inc. | $1,681.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578642 |
| Principal investigator 1 | Genentech, Inc. | $1,534.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578645 |
| Principal investigator 1 | Genentech, Inc. | $2,194.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578649 |
| Principal investigator 1 | Genentech, Inc. | $1,825.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578653 |
| Principal investigator 1 | Genentech, Inc. | $1,825.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578661 |
| Principal investigator 1 | Genentech, Inc. | $1,825.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578665 |
| Principal investigator 1 | Genentech, Inc. | $2,194.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578669 |
| Principal investigator 1 | Genentech, Inc. | $1,395.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578674 |
| Principal investigator 1 | Genentech, Inc. | $1,395.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578678 |
| Principal investigator 1 | Genentech, Inc. | $1,534.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578683 |
| Principal investigator 1 | Genentech, Inc. | $1,681.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578687 |
| Principal investigator 1 | Genentech, Inc. | $1,395.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578696 |
| Principal investigator 1 | Genentech, Inc. | $1,534.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578701 |
| Principal investigator 1 | Genentech, Inc. | $1,825.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578705 |
| Principal investigator 1 | Genentech, Inc. | $2,194.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578713 |
| Principal investigator 1 | Genentech, Inc. | $1,534.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578717 |
| Principal investigator 1 | Genentech, Inc. | $1,681.00 | 06/18/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578720 |
| Principal investigator 1 | Incyte Corporation | $1,195.00 | 06/18/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508121 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,295.00 | 06/16/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099113 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $35.00 | 06/16/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099119 |
| Principal investigator 1 | Incyte Corporation | $680.50 | 06/13/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508163 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,487.50 | 06/11/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158447 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,007.20 | 06/09/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099101 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $840.00 | 06/09/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226099108 |
| Principal investigator 1 | Incyte Corporation | $99.12 | 06/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527829 |
| Principal investigator 1 | Incyte Corporation | $77.75 | 06/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527840 |
| Principal investigator 1 | Incyte Corporation | $19.20 | 06/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527852 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 06/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527855 |
| Principal investigator 1 | Incyte Corporation | $7.84 | 06/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527861 |
| Principal investigator 1 | Incyte Corporation | $231.40 | 06/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527865 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 06/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527869 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 06/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527873 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 06/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527877 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $415.00 | 05/27/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099088 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,570.00 | 05/27/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099094 |
| Principal investigator 1 | Genentech, Inc. | $123.00 | 05/23/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578626 |
| Principal investigator 1 | Genentech, Inc. | $838.00 | 05/23/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578657 |
| Principal investigator 1 | Genentech, Inc. | $169.00 | 05/23/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578709 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 05/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508001 |
| Principal investigator 1 | Incyte Corporation | $94.00 | 05/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508005 |
| Principal investigator 1 | Incyte Corporation | $20.00 | 05/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508019 |
| Principal investigator 1 | Incyte Corporation | $59.00 | 05/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508125 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 05/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508173 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,579.00 | 05/19/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099079 |
| Principal investigator 1 | Incyte Corporation | $954.10 | 05/14/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507997 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 05/14/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508009 |
| Principal investigator 1 | Incyte Corporation | $1,479.00 | 05/14/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508013 |
| Principal investigator 1 | Incyte Corporation | $1,460.00 | 05/14/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508016 |
| Principal investigator 1 | Incyte Corporation | $188.00 | 05/14/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508037 |
| Principal investigator 1 | Incyte Corporation | $118.00 | 05/14/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508108 |
| Principal investigator 1 | Incyte Corporation | $1,560.00 | 05/14/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508182 |
| Principal investigator 1 | Incyte Corporation | $898.90 | 05/12/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508025 |
| Principal investigator 1 | Incyte Corporation | $1,766.00 | 05/12/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508045 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,300.00 | 05/12/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099072 |
| Principal investigator 1 | Genentech, Inc. | $7,793.00 | 05/05/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578692 |
| Principal investigator 1 | Genentech, Inc. | $3,500.00 | 05/05/2025 | Non-covered Recipient Entity Best Skin Research | VELARITE | No dispute reported | 06/30/2026 | 1211578724 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,932.50 | 05/05/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099067 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507970 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507979 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507994 |
| Principal investigator 1 | Incyte Corporation | $164.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508022 |
| Principal investigator 1 | Incyte Corporation | $123.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508030 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508033 |
| Principal investigator 1 | Incyte Corporation | $41.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508040 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508049 |
| Principal investigator 1 | Incyte Corporation | $1,155.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508053 |
| Principal investigator 1 | Incyte Corporation | $231.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508057 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508063 |
| Principal investigator 1 | Incyte Corporation | $120.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508067 |
| Principal investigator 1 | Incyte Corporation | $123.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508071 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508075 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508079 |
| Principal investigator 1 | Incyte Corporation | $184.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508087 |
| Principal investigator 1 | Incyte Corporation | $184.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508092 |
| Principal investigator 1 | Incyte Corporation | $924.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508096 |
| Principal investigator 1 | Incyte Corporation | $275.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508112 |
| Principal investigator 1 | Incyte Corporation | $94.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508129 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508142 |
| Principal investigator 1 | Incyte Corporation | $186.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508146 |
| Principal investigator 1 | Incyte Corporation | $162.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508150 |
| Principal investigator 1 | Incyte Corporation | $465.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508154 |
| Principal investigator 1 | Incyte Corporation | $465.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508159 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508178 |
| Principal investigator 1 | Incyte Corporation | $275.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240508193 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 05/02/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508200 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,750.00 | 04/25/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158440 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 04/25/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226158444 |
| Principal investigator 1 | Amgen Inc. | $59,563.35 | 04/24/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH LLC | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246639607 |
| Principal investigator 1 | Incyte Corporation | $1,640.00 | 04/23/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240507928 |
| Principal investigator 1 | Incyte Corporation | $2,590.00 | 04/23/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240508197 |
| Principal investigator 1 | Eli Lilly and Company | $5,750.00 | 04/21/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH LLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN THE TREATMENT OF ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187878139 |
| Principal investigator 1 | Eli Lilly and Company | $3,000.00 | 04/21/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH LLC | A STUDY OF LY3454738 IN THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187881248 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,383.00 | 04/21/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226099126 |
| Principal investigator 1 | Incyte Corporation | $1,479.00 | 04/16/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507899 |
| Principal investigator 1 | Incyte Corporation | $1,639.00 | 04/16/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507916 |
| Principal investigator 1 | Incyte Corporation | $1,019.30 | 04/16/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507920 |
| Principal investigator 1 | Incyte Corporation | $996.50 | 04/14/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507924 |
| Principal investigator 1 | Incyte Corporation | $1,195.00 | 04/14/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507963 |
| Principal investigator 1 | Incyte Corporation | $1,673.00 | 04/11/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507903 |
| Principal investigator 1 | Incyte Corporation | $1,015.90 | 04/11/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507941 |
| Principal investigator 1 | Incyte Corporation | $1,479.00 | 04/11/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508189 |
| Principal investigator 1 | CSL Behring | $8,000.00 | 04/09/2025 | Non-covered Recipient Entity Best Skin Research | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252669558 |
| Principal investigator 1 | Incyte Corporation | $539.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507907 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507912 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507932 |
| Principal investigator 1 | Incyte Corporation | $205.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507936 |
| Principal investigator 1 | Incyte Corporation | $255.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507945 |
| Principal investigator 1 | Incyte Corporation | $323.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507951 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507954 |
| Principal investigator 1 | Incyte Corporation | $82.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507959 |
| Principal investigator 1 | Incyte Corporation | $164.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507986 |
| Principal investigator 1 | Incyte Corporation | $59.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508134 |
| Principal investigator 1 | Incyte Corporation | $59.00 | 04/09/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508184 |
| Principal investigator 1 | Eli Lilly and Company | $2,700.00 | 04/08/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH LLC | A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1187874849 |
| Principal investigator 1 | Incyte Corporation | $202.00 | 04/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507967 |
| Principal investigator 1 | Incyte Corporation | $164.00 | 04/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507974 |
| Principal investigator 1 | Incyte Corporation | $646.00 | 04/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507982 |
| Principal investigator 1 | Incyte Corporation | $85.00 | 04/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507990 |
| Principal investigator 1 | Incyte Corporation | $118.00 | 04/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508138 |
| Principal investigator 1 | Incyte Corporation | $1,250.00 | 04/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240508167 |
| Principal investigator 1 | Incyte Corporation | $77.75 | 04/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527833 |
| Principal investigator 1 | Incyte Corporation | $119.04 | 04/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527836 |
| Principal investigator 1 | Incyte Corporation | $297.36 | 04/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527844 |
| Principal investigator 1 | Incyte Corporation | $244.92 | 04/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527847 |
| Principal investigator 1 | Incyte Corporation | $244.92 | 04/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527881 |
| Principal investigator 1 | Incyte Corporation | $244.92 | 04/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527885 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $965.00 | 04/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226098909 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,224.60 | 04/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098927 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $910.00 | 04/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098932 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,556.00 | 04/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098939 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,533.30 | 04/02/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226098962 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 03/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098868 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $300.00 | 03/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226098874 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 03/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098885 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,028.00 | 03/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226098897 |
| Principal investigator 1 | Incyte Corporation | $1,331.10 | 03/19/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507727 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 03/17/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226098879 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507655 |
| Principal investigator 1 | Incyte Corporation | $372.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507706 |
| Principal investigator 1 | Incyte Corporation | $184.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507710 |
| Principal investigator 1 | Incyte Corporation | $171.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507714 |
| Principal investigator 1 | Incyte Corporation | $123.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507721 |
| Principal investigator 1 | Incyte Corporation | $924.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507731 |
| Principal investigator 1 | Incyte Corporation | $397.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507738 |
| Principal investigator 1 | Incyte Corporation | $279.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507743 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507747 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507758 |
| Principal investigator 1 | Incyte Corporation | $123.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507762 |
| Principal investigator 1 | Incyte Corporation | $220.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507834 |
| Principal investigator 1 | Incyte Corporation | $1,800.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507861 |
| Principal investigator 1 | Incyte Corporation | $165.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507864 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 03/10/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507872 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,290.00 | 03/10/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226099028 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,997.82 | 03/10/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226099035 |
| Principal investigator 1 | Incyte Corporation | $1,528.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507735 |
| Principal investigator 1 | Incyte Corporation | $1,445.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507751 |
| Principal investigator 1 | Incyte Corporation | $1,445.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507755 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507767 |
| Principal investigator 1 | Incyte Corporation | $1,326.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507771 |
| Principal investigator 1 | Incyte Corporation | $1,326.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507776 |
| Principal investigator 1 | Incyte Corporation | $1,528.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507780 |
| Principal investigator 1 | Incyte Corporation | $1,255.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507784 |
| Principal investigator 1 | Incyte Corporation | $1,445.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507789 |
| Principal investigator 1 | Incyte Corporation | $1,195.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507793 |
| Principal investigator 1 | Incyte Corporation | $1,195.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507797 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507802 |
| Principal investigator 1 | Incyte Corporation | $1,326.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507807 |
| Principal investigator 1 | Incyte Corporation | $1,240.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507810 |
| Principal investigator 1 | Incyte Corporation | $1,240.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507817 |
| Principal investigator 1 | Incyte Corporation | $1,766.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507821 |
| Principal investigator 1 | Incyte Corporation | $1,935.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507825 |
| Principal investigator 1 | Incyte Corporation | $1,935.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507829 |
| Principal investigator 1 | Incyte Corporation | $606.90 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507842 |
| Principal investigator 1 | Incyte Corporation | $1,314.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507846 |
| Principal investigator 1 | Incyte Corporation | $1,195.00 | 03/07/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240507896 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,070.00 | 03/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098967 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $460.00 | 03/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098976 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,860.00 | 03/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098982 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,414.00 | 03/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098988 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,365.00 | 03/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098996 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,365.00 | 03/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226099002 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $585.00 | 03/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226099008 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,201.52 | 03/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226099013 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,321.11 | 03/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226099020 |
| Principal investigator 1 | Incyte Corporation | $1,639.00 | 03/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507639 |
| Principal investigator 1 | Incyte Corporation | $1,167.20 | 03/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507838 |
| Principal investigator 1 | Incyte Corporation | $229.00 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527737 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527743 |
| Principal investigator 1 | Incyte Corporation | $231.40 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527756 |
| Principal investigator 1 | Incyte Corporation | $77.75 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527764 |
| Principal investigator 1 | Incyte Corporation | $129.44 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527772 |
| Principal investigator 1 | Incyte Corporation | $98.72 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527775 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527779 |
| Principal investigator 1 | Incyte Corporation | $19.60 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527784 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527799 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527803 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 03/03/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527808 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,392.00 | 02/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098944 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,269.00 | 02/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098952 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,042.00 | 02/24/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226098957 |
| Principal investigator 1 | Incyte Corporation | $1,329.10 | 02/21/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507652 |
| Principal investigator 1 | Incyte Corporation | $1,460.00 | 02/21/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507672 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,752.00 | 02/10/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098914 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $310.00 | 02/10/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098921 |
| Principal investigator 1 | Eli Lilly and Company | $226,921.00 | 02/05/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH LLC | A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1187874851 |
| Principal investigator 1 | Incyte Corporation | $155.50 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527700 |
| Principal investigator 1 | Incyte Corporation | $8.50 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527721 |
| Principal investigator 1 | Incyte Corporation | $52.48 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527734 |
| Principal investigator 1 | Incyte Corporation | $6.22 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527748 |
| Principal investigator 1 | Incyte Corporation | $155.50 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527752 |
| Principal investigator 1 | Incyte Corporation | $4.25 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527760 |
| Principal investigator 1 | Incyte Corporation | $93.30 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527768 |
| Principal investigator 1 | Incyte Corporation | $77.75 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527788 |
| Principal investigator 1 | Incyte Corporation | $77.75 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527792 |
| Principal investigator 1 | Incyte Corporation | $17.00 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527796 |
| Principal investigator 1 | Incyte Corporation | $93.30 | 02/05/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240527825 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,508.00 | 02/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226098891 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,420.00 | 02/04/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226098903 |
| Principal investigator 1 | Incyte Corporation | $2,315.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507643 |
| Principal investigator 1 | Incyte Corporation | $1,758.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507647 |
| Principal investigator 1 | Incyte Corporation | $2,315.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507659 |
| Principal investigator 1 | Incyte Corporation | $2,315.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507664 |
| Principal investigator 1 | Incyte Corporation | $1,479.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507668 |
| Principal investigator 1 | Incyte Corporation | $1,758.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507675 |
| Principal investigator 1 | Incyte Corporation | $1,758.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507678 |
| Principal investigator 1 | Incyte Corporation | $1,639.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507681 |
| Principal investigator 1 | Incyte Corporation | $2,315.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507685 |
| Principal investigator 1 | Incyte Corporation | $539.10 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507688 |
| Principal investigator 1 | Incyte Corporation | $1,479.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507693 |
| Principal investigator 1 | Incyte Corporation | $1,479.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507697 |
| Principal investigator 1 | Incyte Corporation | $1,560.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507701 |
| Principal investigator 1 | Incyte Corporation | $2,664.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507718 |
| Principal investigator 1 | Incyte Corporation | $1,673.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507850 |
| Principal investigator 1 | Incyte Corporation | $1,673.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507853 |
| Principal investigator 1 | Incyte Corporation | $1,673.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507857 |
| Principal investigator 1 | Incyte Corporation | $1,758.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507868 |
| Principal investigator 1 | Incyte Corporation | $2,664.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507876 |
| Principal investigator 1 | Incyte Corporation | $2,664.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507880 |
| Principal investigator 1 | Incyte Corporation | $2,664.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507885 |
| Principal investigator 1 | Incyte Corporation | $1,479.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507888 |
| Principal investigator 1 | Incyte Corporation | $1,479.00 | 02/03/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240507892 |
| Principal investigator 1 | Amgen Inc. | $19,874.55 | 01/27/2025 | Non-covered Recipient Entity BEST SKIN RESEARCH | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246639609 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,632.50 | 01/21/2025 | Non-covered Recipient Entity Best Skin Research Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226098861 |
| Principal investigator 1 | Incyte Corporation | $120.00 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527692 |
| Principal investigator 1 | Incyte Corporation | $84.48 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527696 |
| Principal investigator 1 | Incyte Corporation | $173.43 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527704 |
| Principal investigator 1 | Incyte Corporation | $17.64 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527709 |
| Principal investigator 1 | Incyte Corporation | $99.12 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527713 |
| Principal investigator 1 | Incyte Corporation | $1.31 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527717 |
| Principal investigator 1 | Incyte Corporation | $371.70 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527725 |
| Principal investigator 1 | Incyte Corporation | $22.89 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527730 |
| Principal investigator 1 | Incyte Corporation | $22.89 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527812 |
| Principal investigator 1 | Incyte Corporation | $22.89 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527817 |
| Principal investigator 1 | Incyte Corporation | $22.89 | 01/02/2025 | Non-covered Recipient Entity DERMDOX DERMATOLOGY CENTERS, PC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240527820 |